Health Technology · Pharmaceuticals: Major · NSE: BAFNAPH · data 2026-10-09
Bafna Pharmaceuticals Limited
Health check: Average (4.6/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹418
Market cap
₹986 cr
P/E
127
P/B
—
ROE
12.3%
ROCE
9.2%
Debt / equity
0.39
Dividend yield
0.00%
1-year return
157.3%
52-week high
₹418
52-week low
₹94.77
Operating margin
3.7%
Growth
| Revenue (last 12 months) | ₹143 cr |
| Net profit (last 12 months) | ₹8 cr |
| Sales growth, 3 years (yearly) | 9.3% |
| Profit growth, 3 years (yearly) | -0.7% |
Chart patterns
- 52-week high — breakout (key level ₹409.85)
Similar companies
Lincoln Pharmaceuticals Ltd (LINCOLN) · Sigachi Industries Limited (SIGACHI) · Bajaj Healthcare Ltd (BAJAJHCARE) · Themis Medicare Limited (THEMISMED) · Shree Ganesh Remedies Ltd. (SGRL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BAFNAPH in NSE Scanner →